BioDelivery Sciences International, Inc. (BDSI)

Market Cap	577.05M
Revenue (ttm)	166.70M
Net Income (ttm)	84.86M
Shares Out	103.23M
EPS (ttm)	0.82
PE Ratio	6.82
Forward PE	15.06
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,107,479
Open	5.60
Previous Close	5.60
Day's Range	n/a
52-Week Range	2.50 - 5.62
Beta	0.56
Analysts	Buy
Price Target	5.48 (-2.0%)
Earnings Date	May 4, 2022

About BDSI

BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products for chronic conditions in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; and Symproic, a peripherally ...

• Industry: Pharmaceuticals
• Founded: 1997
• CEO: Jeffrey Bailey
• Employees: 200
• Stock Exchange: NASDAQ
• Ticker Symbol: BDSI

Full Company Profile

Financial Performance

In 2021, BDSI's revenue was $166.70 million, an increase of 6.54% compared to the previous year's $156.47 million. Earnings were $84.86 million, an increase of 230.05%.

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for BDSI stock is "Buy." The 12-month stock price forecast is 5.48, which is a decrease of -1.97% from the latest price.

Price Target

$5.48

(-1.97% downside)

Analyst Consensus: Buy

Stock Forecasts